Literature DB >> 8851579

Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.

A Ayestarán1, R M López, J B Montoro, A Estíbalez, L Pou, A Julià, A López, B Pascual.   

Abstract

The pharmacokinetics of amphotericin B administered in a conventional 5% dextrose (glucose) (5% D) solution and in a 20% fat emulsion formulation (Intralipid; 20% IL) were compared in 16 patients (mean age, 42 years [range, 18 to 70 years]) who had been hospitalized for hematological malignancies and with proven or suspected fungal infections. All of the patients received 50 mg (approximately 1 mg/kg of body weight per day) of amphotericin B daily in random order, either as a 50-ml lipid emulsion (20% IL) (group I) or in 500 ml of 5% D (group II). Five serum samples were taken during the 24 h after drug administration, and the levels of amphotericin B were measured by high-pressure liquid chromatography. Serum amphotericin B concentrations declined rapidly during the first 6 h, and subsequent measurements revealed a slow terminal elimination phase in both groups. The maximum serum amphotericin B concentration was significantly lower when the drug was administered in 20% IL (1.46 +/- 0.61 versus 2.83 +/- 1.17 micrograms/ml; P = 0.02). The area under the concentration-time curve from 0 to 24 h was also much lower in group I (17.22 +/- 11.15 versus 28.98 +/- 15.46 micrograms.h/ml). The half-life of the distribution phase was approximately three times longer in group I (2.92 +/- 2.34 h versus 0.64 +/- 0.24 h; P = 0.011). Conversely, the half-lives of the elimination phase were approximately equal in the two groups (11.44 +/- 5.18 versus 15.23 +/- 5.25 h). The mean residence times were also similar in both groups (19.41 +/- 11.13 versus 19.65 +/- 7.86 h). The clearance and the steady-state volume of distribution of amphotericin B in group I were about twice as great as those in group II (62.97 +/- 35.51 versus 33.01 +/- 14.33 ml/kg/h and 1,043.92 +/- 512.10 versus 562.32 +/- 152.05 ml/kg [P = 0.034], respectively). Finally, the volume of distribution in the central compartment was greater in group I than in group II (618.17 +/- 231.80 versus 328.19 +/- 151.71 ml/kg; P = 0.013), but there were no differences in the volume of distribution in the peripheral compartment (425.75 +/- 352.87 versus 234.14 +/- 75.92 ml/kg). These results suggest that amphotericin B has a different pharmacokinetic profile when it is administered in 20% IL than when it is administered in the standard 5% D form and that the main difference is due to a clear-cut difference in the steady-state volume of distribution, especially that in the central compartment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851579      PMCID: PMC163166     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.

Authors:  V Heinemann; B Kähny; A Debus; K Wachholz; U Jehn
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

2.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Unusual lipid structures selectively reduce the toxicity of amphotericin B.

Authors:  A S Janoff; L T Boni; M C Popescu; S R Minchey; P R Cullis; T D Madden; T Taraschi; S M Gruner; E Shyamsunder; M W Tate
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 4.  Amphotericin B and its delivery by liposomal and lipid formulations.

Authors:  C Gates; R J Pinney
Journal:  J Clin Pharm Ther       Date:  1993-06       Impact factor: 2.512

Review 5.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

6.  Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

Authors:  P Y Chavanet; I Garry; N Charlier; D Caillot; J P Kisterman; M D'Athis; H Portier
Journal:  BMJ       Date:  1992-10-17

7.  Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.

Authors:  D Caillot; O Casasnovas; E Solary; P Chavanet; B Bonnotte; G Reny; F Entezam; J Lopez; A Bonnin; H Guy
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

8.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.

Authors:  G G Granich; G S Kobayashi; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

9.  Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.

Authors:  P Moreau; N Milpied; N Fayette; J F Ramée; J L Harousseau
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

10.  [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].

Authors:  P Chavanet; N Charlier; A Brenet; A Goux; E Muggéo; D Caillot; O Casasnovas; J P Kistermann; A Waldner; H Portier
Journal:  Pathol Biol (Paris)       Date:  1992-05
View more
  18 in total

1.  Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Joseph Meletiadis; Rafal Al-Saigh; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides; Loukia Zerva
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

5.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Population pharmacokinetics of amphotericin B in children with malignant diseases.

Authors:  C E Nath; A J McLachlan; P J Shaw; R Gunning; J W Earl
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

7.  Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.

Authors:  C E Nath; P J Shaw; R Gunning; A J McLachlan; J W Earl
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Rafal Al-Saigh; Maria Siopi; Nikolaos Siafakas; Aristea Velegraki; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

10.  Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.

Authors:  A Elefanti; J W Mouton; P E Verweij; L Zerva; J Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.